Company profile for Blue Lake Biotechnology

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Blue Lake Biotechnology, Inc., a clinical-stage biopharmaceutical company developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BLB-201, an intranasal vaccine for the prevention of respiratory syncytial virus (RSV) associated disease in adults over 60 and children under 2 years o...
Blue Lake Biotechnology, Inc., a clinical-stage biopharmaceutical company developing vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for BLB-201, an intranasal vaccine for the prevention of respiratory syncytial virus (RSV) associated disease in adults over 60 and children under 2 years of age.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
111 Riverbend Road, Athens, GA 30602
Telephone
Telephone
(706) 201-7798
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251121851216/en/Blue-Lake-Biotechnology-to-Resume-Enrollment-of-RSV-negative-Toddlers-in-Phase-12a-Clinical-Trial-of-BLB201

BUSINESSWIRE
21 Nov 2025

https://www.businesswire.com/news/home/20250707039979/en/Blue-Lake-and-CyanVac-Publish-Full-Data-from-Open-Label-Phase-1-Clinical-Study-of-COVID-19-Vaccine-Candidate

BUSINESSWIRE
07 Jul 2025

https://www.businesswire.com/news/home/20250327538811/en/Preclinical-Intranasal-COVID-19-Vaccine-Candidate-Data-Demonstrate-Durable-Immune-Response-and-Broad-Protection

BUSINESSWIRE
27 Mar 2025

https://www.businesswire.com/news/home/20250310402095/en

BUSINESSWIRE
10 Mar 2025

https://www.businesswire.com/news/home/20241212054564/en

BUSINESSWIRE
12 Dec 2024

https://www.businesswire.com/news/home/20241020038518/en

BUSINESSWIRE
21 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty